These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31679120)

  • 21. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Franke RM; Morton T; Devarakonda K
    Drug Des Devel Ther; 2015; 9():4587-97. PubMed ID: 26316698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.
    Devarakonda K; Morton T; Margulis R; Giuliani M; Barrett T
    Drug Des Devel Ther; 2014; 8():1125-34. PubMed ID: 25170252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet.
    Lux EA; Janecki M; Maritz MA
    Curr Med Res Opin; 2014 Nov; 30(11):2365-75. PubMed ID: 25050592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two clinical trials.
    Wilson JG; Bass A; Pixton GC; Wolfram G; Rauck RL
    Curr Med Res Opin; 2020 Jan; 36(1):91-99. PubMed ID: 31456431
    [No Abstract]   [Full Text] [Related]  

  • 26. Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study.
    Webster LR; Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Jul; 36(7):1730-1740. PubMed ID: 31065992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the effect of naltrexone coadministration on the pharmacokinetics of oxycodone in a randomized phase 1 clinical trial
.
    Kleideiter E; Buller S; Nemeth R; Terlinden R; Rengelshausen J
    Int J Clin Pharmacol Ther; 2020 Aug; 58(8):439-448. PubMed ID: 32507128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxycodone with an opioid receptor antagonist: A review.
    Davis MP; Goforth HW
    J Opioid Manag; 2016; 12(1):67-85. PubMed ID: 26908305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the tamper-resistant properties of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Eisenhauer TD; Matchett M; Heasley R; Morton T; Devarakonda K; Giuliani M; Young JL; Barrett T
    Drug Dev Ind Pharm; 2016 Jan; 42(1):157-165. PubMed ID: 26146769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets.
    Kim JY; Lee SH; Park CW; Rhee YS; Kim DW; Park J; Lee M; Seo JW; Park ES
    Drug Des Devel Ther; 2015; 9():695-706. PubMed ID: 25678774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.
    Webster LR; Kopecky EA; Smith MD; Fleming AB
    Pain Med; 2016 Jun; 17(6):1112-30. PubMed ID: 26814256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends and uptake of new formulations of controlled-release oxycodone in Canada.
    Gomes T; Jain S; Paterson JM; Sketris I; Caetano P; Henry D;
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):520-525. PubMed ID: 29359446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza
    Gudin J
    J Opioid Manag; 2020; 16(2):127-139. PubMed ID: 32329888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical relevance of the pharmacokinetic characteristics of an abuse-deterrent, extended-release, injection-molded morphine tablet.
    Dayno JM; Niebler G; Lawler J; Elhauge T; Lindhardt K
    J Opioid Manag; 2017; 13(2):111-124. PubMed ID: 28829526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets.
    Morton T; Franke R; Devarakonda K
    Pain Pract; 2016 Jul; 16(6):730-6. PubMed ID: 26218586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The comparative pharmacokinetics of physical manipulation by crushing of Xtampza
    Brennan MJ; Kopecky EA; Marseilles A; O'Connor M; Fleming AB
    Pain Manag; 2017 Nov; 7(6):461-472. PubMed ID: 29171358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
    Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
    Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia.
    McCarberg BH; Kopecky EA; O'Connor M; Marseilles A; Varanasi RK; Thompson C; Fleming AB
    Curr Med Res Opin; 2016 Dec; 32(12):1975-1982. PubMed ID: 27668546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
    Webster LR; Iverson M; Pantaleon C; Smith MD; Kinzler ER; Aigner S
    Pain Med; 2019 Apr; 20(4):747-757. PubMed ID: 29608768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.